Join the Oncology Voice Network. Join for Free
Aspiring MSL Insight: What Types of MSL Presentations are Acceptable in a Final Interview?

Aspiring MSL Insight: What Types of MSL Presentations are Acceptable in a Final Interview?


Share This Article


Aspiring MSL Insight: What Types of MSL Presentations are Acceptable in a Final Interview? 🧑‍⚕️🎤

If you’re an Aspiring MSL, you likely realize how important the MSL presentation is during the final interview. But you may be wondering, “What type of presentation should I do? 🤔"

So, for this Aspiring MSL Insight, Michael Pietrack describes the top three types of MSL presentations that are acceptable in a final interview.

1️⃣ The most common type of presentation used in MSL interviews is the clinical data presentation. 📊 This is a good style to showcase your ability to understand and communicate scientific data effectively. If this is the route you take, choose a recent, relevant study and provide a comprehensive overview, including the study design, methodology, results, and implications. So, the most common type is a clinical data presentation.

2️⃣ The second most common presentation type is a therapy overview presentation. 💊 This type of presentation will showcase your knowledge of the therapeutic area and the company’s products, because you’ll be providing an in-depth overview of a particular drug’s mechanism of action or how that drug fits into the current treatment landscape. So, the second type is a therapy overview.

3️⃣ The third most common type of presentation given at a final interview for an MSL job is a journal club style presentation. 📚 In the pharmaceutical industry, a journal club is a formal meeting where individuals (typically healthcare professionals, researchers, or members of a pharmaceutical company) gather to critically evaluate and discuss recent articles from scientific journals. If you go this route, choose a recent and relevant article from a highly-respected journal that addresses a significant question or an advancement in the field.

Subscribe to the channel

Follow Michael Pietrack on LinkedIn

Join our private LinkedIn Job Board: "KBIC Jobs - Medical Affairs"

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Podcast
The Ideal Roadmap for New MSLs
Partner Avatar MSL Talk: Tom Caravela, Sarah Snyder

The Ideal Roadmap for New MSLs

Article
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
OVN Avatar B. Gyawali, E. G. E. de Vries, U. Dafni, T. Amaral, J. Barriuso, J. Bogaerts, A. Calles, G. Curigliano, C. Gomez-Roca, B. Kiesewetter, S. Oosting, A. Passaro, G. Pentheroudakis, M. Piccart, F. Roitberg, J. Tabernero, N. Tarazona, D. Trapani, R. Wester, G.

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Explore OVN